Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all?

Translational Psychiatry

Volumn 5, Issue 7, 2015, Pages

  van Buel, E M ^a,b   Patas, K ^a,c   Peters, M ^a   Bosker, F J ^b   Eisel, U L M ^a,b   Klein, H C ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR;

DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; HUMAN; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; HUMANS; INFLAMMATION; NERVE GROWTH FACTORS; TREATMENT OUTCOME;

EID: 84965189787     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2015.100     Document Type: Article

References (128)

1. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9: 87–98.
2. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 54–63.
3. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsycho-pharmacology 2000; 23: 477–501.
4. Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE et al. Disturbance of the gluta-matergic system in mood disorders. Exp Neurobiol 2014; 23: 28–35.
5. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007; 18: 391–418.
6. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732–741.
7. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsycho-pharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012; 37: 137–162.
8. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361: 799–808.
9. Heijnen WT, Birkenhager TK, Wierdsma AI, van den Broek WW. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol 2010; 30: 616–619.
10. Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT 2014; 30: 5–9.
11. Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntington's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 209–210.
12. Popeo D, Kellner CH. ECT for Parkinson’s disease. Med Hypotheses 2009; 73: 468–469.
13. Zervas IM, Theleritis C, Soldatos CR. Using ECT in schizophrenia: a review from a clinical perspective. World J Biol Psychiatry 2012; 13: 96–105.
14. Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci 2013; 70: 4259–4273.
15. Ellrichmann G, Reick C, Saft C, Linker RA. The role of the immune system in Huntington's disease. Clin Dev Immunol 2013; 2013: 541259.
16. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry 2014; doi: 10.1038/mp.2014.117.
17. Gil-Mohapel J, Simpson JM, Ghilan M, Christie BR. Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies? Brain Res 2011; 1406: 84–105.
18. Marxreiter F, Regensburger M, Winkler J. Adult neurogenesis in Parkinson's disease. Cell Mol Life Sci 2013; 70: 459–473.
19. Pickard B. Progress in defining the biological causes of schizophrenia. Expert Rev Mol Med 2011; 13: e25.
20. Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neu-roinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 277–286.
21. Miller BR, Hen R. The current state of the neurogenic theory of depression and anxiety. Curr Opin Neurobiol 2014; 30C: 51–58.
22. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19: 5034–5043.
23. MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 2003; 100: 1387–1392.
24. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805–809.
25. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011; 476: 458–461.
26. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104–9110.
27. Duman RS, Vaidya VA. Molecular and cellular actions of chronic electro-convulsive seizures. J ECT 1998; 14: 181–193.
28. Perera TD, Coplan JD, Lisanby SH, Lipira CM, Arif M, Carpio C et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 2007; 27: 4894–4901.
29. Nordanskog P, Dahlstrand U, Larsson MR, Larsson EM, Knutsson L, Johanson A. Increase in hippocampal volume after electroconvulsive therapy in patients with depression: a volumetric magnetic resonance imaging study. J ECT 2010; 26: 62–67.
30. Dukart J, Regen F, Kherif F, Colla M, Bajbouj M, Heuser I et al. Electroconvulsive therapy-induced brain plasticity determines therapeutic outcome in mood dis-orders. Proc Natl Acad Sci USA 2014; 111: 1156–1161.
31. Lee E, Son H. Adult hippocampal neurogenesis and related neurotrophic factors. BMB Rep 2009; 42: 239–244.
32. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood dis-orders. Biol Psychiatry 2006; 59: 1116–1127.
33. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippo-campal BDNF immunoreactivity in subjects treated with antidepressant medi-cation. Biol Psychiatry 2001; 50: 260–265.
34. Zhang Y, Gu F, Chen J, Dong W. Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res 2010; 1366: 141–148.
35. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neu-rotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251–3261.
36. Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W et al. Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 2005; 25: 6243–6250.
37. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA. Electroconvulsive stimuli alter the regional concentrations of nerve growth factor, brain-derived neuro-trophic factor, and glial cell line-derived neurotrophic factor in adult rat brain. J ECT 2002; 18: 138–143.
38. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electro-convulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703–709.
39. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539–7547.
40. Kang UG, Koo YJ, Jeon WJ, Park DB, Juhnn YS, Park JB et al. Activation of extracellular signal-regulated kinase signaling by chronic electroconvulsive shock in the rat frontal cortex. Psychiatry Res 2006; 145: 75–78.
41. Kang UG, Roh MS, Jung JR, Shin SY, Lee YH, Park JB et al. Activation of protein kinase B (Akt) signaling after electroconvulsive shock in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 41–44.
42. Kyeremanteng C, James J, Mackay J, Merali Z. A study of brain and serum brain-derived neurotrophic factor protein in Wistar and Wistar-Kyoto rat strains after electroconvulsive stimulus. Pharmacopsychiatry 2012; 45: 244–249.
43. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 2014; 19: 791–800.
44. Lanz TA, Bove SE, Pilsmaker CD, Mariga A, Drummond EM, Cadelina GW et al. Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma. Biomarkers 2012; 17: 524–531.
45. Sariola H. The neurotrophic factors in non-neuronal tissues. Cell Mol Life Sci 2001; 58: 1061–1066.
46. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553–1561.
47. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010; 35: 2378–2391.
48. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009; 42: 270–276.
49. Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, Abate M, Segala M, Giacopuzzi M et al. Electroconvulsive therapy (ECT) increases serum brain derived neuro-trophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsycho-pharmacol 2006; 16: 620–624.
50. Haghighi M, Salehi I, Erfani P, Jahangard L, Bajoghli H, Holsboer-Trachsler E et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J Psychiatr Res 2013; 47: 908–915.
51. Hu Y, Yu X, Yang F, Si T, Wang W, Tan Y et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT 2010; 26: 121–125.
52. Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 2007; 68: 512–517.
53. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Inoue Y et al. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1185–1190.
54. Piccinni A, Del Debbio A, Medda P, Bianchi C, Roncaglia I, Veltri A et al. Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 2009; 19: 349–355.
55. Fernandes B, Gama CS, Massuda R, Torres M, Camargo D, Kunz M et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neurosci Lett 2009; 453: 195–198.
56. Gronli O, Stensland GO, Wynn R, Olstad R. Neurotrophic factors in serum following ECT: a pilot study. World J Biol Psychiatry 2009; 10: 295–301.
57. Lin CH, Chen MC, Lee WK, Chen CC, Huang CH, Lane HY. Electroconvulsive therapy improves clinical manifestation with plasma BDNF levels unchanged in treatment-resistant depression patients. Neuropsychobiology 2013; 68: 110–115.
58. Bumb JM, Aksay SS, Janke C, Kranaster L, Geisel O, Gass P et al. Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients. Eur Arch Psychiatry Clin Neurosci 2015; 265: 227–232.
59. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002; 99: 11946–11950.
60. Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 2004; 14: 237–248.
61. Segi-Nishida E, Warner-Schmidt J, Duman R,S. Electroconvulsive seizure and VEGF increase the proliferation of neural-stem-like cells in rat hippocampus. Proc Natl Acad Sci USA 2008; 105: 11352–11357.
62. Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007; 104: 4647–4652.
63. Licht T, Goshen I, Avital A, Kreisel T, Zubedat S, Eavri R et al. Reversible mod-ulations of neuronal plasticity by VEGF. Proc Natl Acad Sci USA 2011; 108: 5081–5086.
64. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 2002; 17: 306–310.
65. Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 2003; 23: 10841–10851.
66. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neu-rogenesis. J Comp Neurol 2000; 425: 479–494.
67. Madsen TM, Yeh DD, Valentine GW, Duman RS. Electroconvulsive seizure treatment increases cell proliferation in rat frontal cortex. Neuropsychopharma-cology 2005; 30: 27–34.
68. Jansson L, Hellsten J, Tingstrom A. Region specific hypothalamic neuronal activation and endothelial cell proliferation in response to electroconvulsive sei-zures. Biol Psychiatry 2006; 60: 874–881.
69. Minelli A, Zanardini R, Abate M, Bortolomasi M, Gennarelli M, Bocchio-Chiavetto L. Vascular endothelial growth factor (VEGF) serum concentration during elec-troconvulsive therapy (ECT) in treatment resistant depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1322–1325.
70. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–457.
71. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2 R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012; 139: 230–239.
72. Vogelzangs N, Duivis HE, Beekman AT, Kluft C, Neuteboom J, Hoogendijk W et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2012; 2: e79.
73. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16: 751–762.
74. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46–56.
75. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011; 13: 467–475.
76. Lehtimaki K, Keranen T, Huuhka M, Palmio J, Hurme M, Leinonen E et al. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT 2008; 24: 88–91.
77. Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003; 19: 183–188.
78. Fluitman SB, Heijnen CJ, Denys DA, Nolen WA, Balk FJ, Westenberg HG. Elec-troconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J Affect Disord 2011; 131: 388–392.
79. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15: 199–226.
80. Chaturvedi S, Chadda RK, Rusia U, Jain N. Effect of electroconvulsive therapy on hematological parameters. Psychiatry Res 2001; 104: 265–268.
81. Albrecht J, Helderman JH, Schlesser MA, Rush AJ. A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiatry Res 1985; 15: 185–193.
82. Fischler B, Bocken R, Schneider I, De Waele M, Thielemans K, Derde MP. Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci 1992; 650: 326–330.
83. Kronfol Z, Nair MP, Weinberg V, Young EA, Aziz M. Acute effects of electro-convulsive therapy on lymphocyte natural killer cell activity in patients with major depression. J Affect Disord 2002; 71: 211–215.
84. Roman A, Nalepa I. Effect of repeated administration of paroxetine and elec-troconvulsive shock on the proliferative response of lymphocytes and the synthesis of nitric oxide by macrophages in rats. J ECT 2005; 21: 111–117.
85. Roman A, Nawrat D, Nalepa I. Chronic treatment with electroconvulsive shock may modulate the immune function of macrophages. J ECT 2008; 24: 260–267.
86. Devi RS, Namasivayam A, Prabhakaran K. Modulation of non-specific immunity by hippocampal stimulation. J Neuroimmunol 1993; 42: 193–197.
87. Jansson L, Orre K, Tingstrom A. Repeated electroconvulsive seizures increase the number of vessel-associated macrophages in rat hippocampus. J ECT 2012; 28: 174–179.
88. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol 2010; 119: 89–105.
89. Jansson L, Wennstrom M, Johanson A, Tingstrom A. Glial cell activation in response to electroconvulsive seizures. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1119–1128.
90. Wennstrom M, Hellsten J, Ekdahl CT, Tingstrom A. Electroconvulsive seizures induce proliferation of NG2-expressing glial cells in adult rat hippocampus. Biol Psychiatry 2003; 54: 1015–1024.
91. Wennstrom M, Hellsten J, Ekstrand J, Lindgren H, Tingstrom A. Corticosterone-induced inhibition of gliogenesis in rat hippocampus is counteracted by elec-troconvulsive seizures. Biol Psychiatry 2006; 59: 178–186.
92. Wennstrom M, Hellsten J, Tingstrom A. Electroconvulsive seizures induce proliferation of NG2-expressing glial cells in adult rat amygdala. Biol Psychiatry 2004; 55: 464–471.
93. Jinno S, Kosaka T. Reduction of Iba1-expressing microglial process density in the hippocampus following electroconvulsive shock. Exp Neurol 2008; 212: 440–447.
94. Rueger MA, Keuters MH, Walberer M, Braun R, Klein R, Sparing R et al. Multi-session transcranial direct current stimulation (tDCS) elicits inflammatory and regenerative processes in the rat brain. PLoS One 2012; 7: e43776.
95. Tabakman R, Lecht S, Sephanova S, Arien-Zakay H, Lazarovici P. Interactions between the cells of the immune and nervous system: neurotrophins as neu-roprotection mediators in CNS injury. Prog Brain Res 2004; 146: 387–401.
96. Vega JA, Garcia-Suarez O, Hannestad J, Perez-Perez M, Germana A. Neuro-trophins and the immune system. J Anat 2003; 203: 1–19.
97. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000; 20: 5283–5291.
98. Besser M, Wank R. Cutting edge: clonally restricted production of the neuro-trophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999; 162: 6303–6306.
99. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE et al. Activated human T cells, B cells, and monocytes produce brain-derived neuro-trophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865–870.
100. Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 2005; 160: 204–209.
101. Patas K, Penninx BW, Bus BA, Vogelzangs N, Molendijk ML, Elzinga BM et al. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain Behav Immun 2014; 36: 71–79.
102. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010; 133: 2248–2263.
103. Schwartz M, Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: the missing link between health and disease. Mol Psychiatry 2010; 15: 342–354.
104. Lee BH, Kim YK. BDNF mRNA expression of peripheral blood mononuclear cells was decreased in depressive patients who had or had not recently attempted suicide. J Affect Disord 2010; 125: 369–373.
105. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 645–651.
106. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are nor-malized by antidepressant treatment. Int J Neuropsychopharmacol 2010; 13: 103–108.
107. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ et al. Candi-date genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013; 38: 377–385.
108. Wang HY, Crupi D, Liu J, Stucky A, Cruciata G, Di Rocco A et al. Repetitive transcranial magnetic stimulation enhances BDNF-TrkB signaling in both brain and lymphocyte. J Neurosci 2011; 31: 11044–11054.
109. Bayas A, Kruse N, Moriabadi NF, Weber F, Hummel V, Wohleben G et al. Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells. Neurosci Lett 2003; 335: 155–158.
110. Rezaee F, Rellick SL, Piedimonte G, Akers SM, O'Leary HA, Martin K et al. Neu-rotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway. PLoS One 2010; 5: e9690.
111. Maroder M, Bellavia D, Meco D, Napolitano M, Stigliano A, Alesse E et al. Expression of trKB neurotrophin receptor during T cell development. Role of brain derived neurotrophic factor in immature thymocyte survival. J Immunol 1996; 157: 2864–2872.
112. Schuhmann B, Dietrich A, Sel S, Hahn C, Klingenspor M, Lommatzsch M et al. A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol 2005; 163: 15–23.
113. Zhang X, Zeng L, Yu T, Xu Y, Pu S, Du D et al. Positive feedback loop of autocrine BDNF from microglia causes prolonged microglia activation. Cell Physiol Biochem 2014; 34: 715–723.
114. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci USA 1998; 95: 5779–5784.
115. Bouhy D, Malgrange B, Multon S, Poirrier AL, Scholtes F, Schoenen J et al. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages. FASEB J 2006; 20: 1239–1241.
116. Thored P, Heldmann U, Gomes-Leal W, Gisler R, Darsalia V, Taneera J et al. Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia 2009; 57: 835–849.
117. Correale J. The role of microglial activation in disease progression. Mult Scler 2014; 20: 1288–1295.
118. Lai AY, Todd KG. Differential regulation of trophic and proinflammatory microglial effectors is dependent on severity of neuronal injury. Glia 2008; 56: 259–270.
119. Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry 2014; 19: 699–709.
120. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are atte-nuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA 2011; 108: 9262–9267.
121. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 2012; 169: 1065–1072.
122. Perez-Caballero L, Perez-Egea R, Romero-Grimaldi C, Puigdemont D, Molet J, Caso JR et al. Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. Mol Psychiatry 2014; 19: 607–614.
123. Vogelzangs N, Beekman AT, van Reedt Dortland AK, Schoevers RA, Giltay EJ, de Jonge P et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology 2014; 39: 1624–1634.
124. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 2013; 18: 692–699.
125. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11: 129–7015-11-129.
126. Cohen IR. Real and artificial immune systems: computing the state of the body. Nat Rev Immunol 2007; 7: 569–574.
127. Schwartz M, Kipnis J, Rivest S, Prat A. How do immune cells support and shape the brain in health, disease, and aging? J Neurosci 2013; 33: 17587–17596.
128. Correale J, Fiol M, Villa A. Neuroprotective effects of inflammation in the nervous system. In: Phelps, Korneva (eds). NeuroImmune Biology. Elsevier, 2008, pp 403–431; ISBN: 978-0-444-53041-7.